Acute coronary syndrome (ACS) Circulatory System
Conditions
Interventions
Randomized controlled trial, Patients taking anti-platelets were randomly allocated into intro either interventional or control arm. Patients were randomized based on automated software called castorE
Sponsors
United Arab Emirates University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Arabian Gulf patients 2. Above 18 years old 3. Diagnosed with acute coronary syndrome (ACS) 4. Planned to take anti-platelets for at least one year
Exclusion criteria
Exclusion criteria: 1. Patients with severe illness 2. Severe renal or hepatic impairment 3. Patients not expected to take dual anti-platelets for a minimum of one year 4. Patients taking long-term anti-coagulants 5. Patients with active tumors and currently under chemotherapy 6. Patients with active bleeding or history of significant bleeding in the past three months 7. Hematologic problems: 7.1. WBC <2 x 10^9 /l 7.2. Platelet counts <100 x 10^9 /l 7.3. Hematocrit <30%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of major adverse cardiovascular events (MACE), including myocardial infarction (MI), ischemic stroke, definite stent thrombosis, severe recurrent ischemia (angina requiring PCI), or death within 12 months following the ACS event measured using patient records at baseline, 4 weeks, 12 weeks, and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Major or minor bleeding events, assessed according to the thrombolysis in myocardial infarction (TIMI) criteria measured using patient records and patient interviews at baseline, 4 weeks, 12 weeks, and 12 months | — |
Countries
United Arab Emirates
Contacts
Public ContactBassam Ali
Outcome results
None listed